Answers are grounded in this paper and cite their sources.
With the development of molecular targeted therapies, a wide array of dermatologic toxicities is appearing. Their prevention, recognition, and management by dermatologists is critical to ensure antineoplastic treatment continuation. The objective of this study was to provide a literature review of the most common dermatologic toxicities due to targeted therapies in oncologic patients, including their clinical presentation, prevention, and management.
No takes yet. Share an insight, caveat, or question.
Dagher et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: